J. Goldman & CO LP Regeneron Pharmaceuticals, Inc. Transaction History

J. Goldman & CO LP

$2.89 Billion
Q1 2024

A detailed history of J. Goldman & CO LP transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 6,598 shares of REGN stock, worth $6.93 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares

6,598

Previous 45,603 85.53%

Holding current value

$6.93 Million

Previous $40.1 Million 84.15%

% of portfolio

0.22%

Previous 1.74%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$902.69 - $993.35 $35.2 Million - $38.7 Million	-39,005 Reduced 85.53%	6,598 $6.35 Million
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $13,178 - $14,988	-17 Reduced 0.04%	45,603 $40.1 Million
Q3 2023 Nov 14, 2023	BUY	$692.45 - $844.37 $17.9 Million - $21.8 Million	25,814 Added 130.33%	45,620 $37.5 Million
Q2 2023 Aug 14, 2023	BUY	$700.03 - $830.35 $12.4 Million - $14.7 Million	17,759 Added 867.56%	19,806 $14.2 Million
Q1 2023 May 15, 2023	SELL	$680.49 - $826.97 $13.5 Million - $16.4 Million	-19,854 Reduced 90.65%	2,047 $1.68 Million

Q4 2022 Feb 14, 2023	BUY	$705.89 - $766.39 $12.6 Million - $13.7 Million	17,867 Added 442.91%	21,901 $15.8 Million
Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $473,525 - $597,564	-825 Reduced 16.98%	4,034 $2.78 Million
Q2 2022 Aug 15, 2022	BUY	$548.35 - $738.84 $2.66 Million - $3.59 Million	4,859 New	4,859 $2.87 Million

Others Institutions Holding REGN

# of Institutions

1,424

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $113B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.

Account